Selective Digestive Tract Decontamination and Selective Oropharyngeal Decontamination and Antibiotic Resistance in Patients in Intensive-care Units: an Open-label, Clustered Group-randomised, Crossover Study
Overview
Authors
Affiliations
Background: Previously, we assessed selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) on survival and prevention of bacteraemia in patients in intensive-care units. In this analysis, we aimed to assess effectiveness of these interventions for prevention of respiratory tract colonisation and bacteraemia with highly resistant microorganisms acquired in intensive-care units.
Methods: We did an open-label, clustered group-randomised, crossover study in 13 intensive-care units in the Netherlands between May, 2004, and July, 2006. Participants admitted to intensive-care units with an expected duration of mechanical ventilation of more than 48 h or an expected stay of more than 72 h received SOD (topical tobramycin, colistin, and amphotericin B in the oropharynx), SDD (SOD antibiotics in the oropharynx and stomach plus 4 days' intravenous cefotaxime), or standard care. The computer-randomised order of study regimens was applied by an independent clinical pharmacist who was masked to intensive-care-unit identity. We calculated crude odds ratios (95% CI) for rates of bacteraemia or respiratory tract colonisation with highly resistant microorganisms in patients who stayed in intensive-care units for more than 3 days (ie, acquired infection). This trial is registered at http://isrctn.org, number ISRCTN35176830.
Findings: Data were available for 5927 (>99%) of 5939 patients, of whom 5463 (92%) were in intensive-care units for more than 3 days. 239 (13%) of 1837 patients in standard care acquired bacteraemia after 3 days, compared with 158 (9%) of 1758 in SOD (odds ratio 0·66, 95% CI 0·53-0·82), and 124 (7%) of 1868 in SDD (0·48, 0·38-0·60). Eight patients acquired bacteraemia with highly resistant microorganisms during SDD, compared with 18 patients (with 19 episodes) during standard care (0·41, 0·18-0·94; rate reduction [RR] 59%, absolute risk reduction [ARR] 0·6%) and 20 during SOD (0·37, 0·16-0·85; RR 63%, ARR 0·7%). Of the patients staying in intensive-care units for more than 3 days, we obtained endotracheal aspirate cultures for 881 (49%) patients receiving standard care, 886 (50%) receiving SOD, and 828 (44%) receiving SDD. 128 (15%) patients acquired respiratory tract colonisation with highly resistant microorganisms during standard care, compared with 74 (8%) during SDD (0·58, 0·43-0·78; RR 38%, ARR 5·5%) and 88 (10%) during SOD (0·65, 0·49-0·87; RR 32%, ARR 4·6%). Acquired respiratory tract colonisation with Gram-negative bacteria or cefotaxime-resistant and colistin-resistant pathogens was lowest during SDD.
Interpretation: Widespread use of SDD and SOD in intensive-care units with low levels of antibiotic resistance is justified.
Funding: None.
Oral nonabsorbable antibiotics for prevention of recurrent cholangitis; a brief report study.
Fortun J, Rodriguez-Gandia M, Pintado V, Martin-Davila P, Garcia-Gonzalez M, Graus J Infection. 2025; .
PMID: 39976806 DOI: 10.1007/s15010-025-02491-2.
Vicente Arranz J, Sanchez-Ramirez C, Saavedra P, Rivero Perdomo Y, Lorenzo-Martin M, Blanco-Lopez J J Clin Med. 2024; 13(14).
PMID: 39064251 PMC: 11278040. DOI: 10.3390/jcm13144211.
Cocker D, Birgand G, Zhu N, Rodriguez-Manzano J, Ahmad R, Jambo K Nat Rev Microbiol. 2024; 22(10):636-649.
PMID: 39048837 DOI: 10.1038/s41579-024-01076-4.
Zwerwer L, Luz C, Soudis D, Giudice N, Nijsten M, Glasner C Sci Rep. 2024; 14(1):2317.
PMID: 38282072 PMC: 10822855. DOI: 10.1038/s41598-024-52741-w.
Pathan N, Woolfall K, Popa M, de la Fuente G, Ferrando-Vivas P, Brown A Sci Rep. 2023; 13(1):21668.
PMID: 38066012 PMC: 10709430. DOI: 10.1038/s41598-023-46232-7.